- Q4 2021 Galmed Pharmaceuticals Ltd Earnings Call TranscriptMay 02, 2022$18.3 (-26.51%)Earnings
- Q3 2021 Galmed Pharmaceuticals Ltd Earnings Call TranscriptNov 08, 2021$44.85 (+6.79%)Earnings
- Q2 2021 Galmed Pharmaceuticals Ltd Earnings Call TranscriptAug 05, 2021$42.9 (+4.38%)Earnings
- Q1 2021 Galmed Pharmaceuticals Ltd Earnings Call TranscriptMay 13, 2021$33.6 (-8.20%)Earnings
- Q4 2020 Galmed Pharmaceuticals Ltd Earnings Call TranscriptMar 18, 2021$51.3 (-2.01%)Earnings
- Galmed Pharmaceuticals Ltd KOL Symposium and Pipeline Update TranscriptJan 26, 2021
- Q3 2020 Galmed Pharmaceuticals Ltd Earnings Call TranscriptNov 12, 2020$47.55 (-5.65%)Earnings
- Q2 2020 Galmed Pharmaceuticals Ltd Earnings Call TranscriptAug 06, 2020$69.15 (-7.24%)Earnings
- Q1 2020 Galmed Pharmaceuticals Ltd Earnings Call TranscriptMay 14, 2020$76.2 (+2.21%)Earnings
- Q4 2019 Galmed Pharmaceuticals Ltd Earnings Call TranscriptMar 12, 2020$50.85 (-19.48%)Earnings
- Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call TranscriptNov 06, 2019$64.05 (-10.11%)Earnings
- Q2 2019 Galmed Pharmaceuticals Ltd Earnings Call TranscriptAug 05, 2019Earnings
Q2 2021 Galmed Pharmaceuticals Ltd Earnings Call Transcript
Good day, and welcome to Galmed conference call to discuss financial results for the second quarter 2021. Today's conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on the beliefs and the expectations of the management of today and actual results, trends, timelines and projections relating to our financial position and projected development program and pipeline could differ materially.
We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our annual report on Form 20-F filed with the SEC and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligation
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)